Congress

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

i-Health, Inc. Urges U.S. Congressional Leaders to Prioritize the Funding of Natural & Non-Hormonal Solutions for Menopause in Women's Health Research

Retrieved on: 
Monday, April 8, 2024
Health, Attention, Congress, Government, Veteran, White, SVP, Executive order, Research, Menopause, History, Woman, Data collection, Hormone replacement therapy, Breast cancer, HRT, Hot, Amerifit Brands

i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.

Key Points: 
  • i-Health, Inc. starts discussions with Congress to enhance research and funding for non-hormonal menopause options.
  • Research gaps are especially prevalent for health conditions associated with women's midlife and later years, including perimenopause and menopause."
  • The latest Executive Order from President Biden aims to close research gaps on women's health across their lifespans.
  • i-Health, Inc. the company behind Estroven®, the leading brand in natural, non-hormonal menopause relief‡, is committed to driving meaningful change for often overlooked health issues.

OAK CREEK HOMES CELEBRATES TRIPLE WIN AT 2024 MANUFACTURED HOUSING AWARDS

Retrieved on: 
Friday, April 5, 2024
MHI, Less, Congress, House, Plant, Luxury, Manufactured Housing Institute, The Crane, OCH, Tornado, Atmosphere, Weather, Living room, HUD, Self storage

LEAGUE CITY, Texas, April 5, 2024 /PRNewswire/ -- Oak Creek Homes (OCH) proudly announces its triumphant win at the 2024 Excellence in Manufactured Housing Awards. Among stiff competition, OCH secured victory in three categories, reaffirming its status as an industry leader in quality and innovation.

Key Points: 
  • LEAGUE CITY, Texas, April 5, 2024 /PRNewswire/ -- Oak Creek Homes (OCH) proudly announces its triumphant win at the 2024 Excellence in Manufactured Housing Awards.
  • Hosted by the Manufactured Housing Institute (MHI) at Congress & Expo , Oak Creek Homes emerged victorious in the Small Volume Manufacturer of the Year – Three Plants or Less, Manufactured Home Design- Multi-section, and Manufactured Home Design – Single-section categories.
  • Founded in 1971 by CEO Buck Teeter, Oak Creek Homes offers a diverse range of high-quality factory-built homes and commercial structures.
  • Explore every room of the Crane and take a video tour here :
    In conclusion, Oak Creek Homes' triple win at the 2024 Excellence in Manufactured Housing Awards underscores the company's unwavering commitment to excellence and innovation.

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

Retrieved on: 
Monday, March 25, 2024
MD, LOS, ERA, European Renal Association, Patient, Kidney disease, Congress, Nephrology, Therapy

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.

Key Points: 
  • LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden.
  • Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “The ERA Congress is one of the most prominent nephrology meetings of the year, and we are excited to deliver presentations on both OLC and UNI-494.
  • In addition to presenting preclinical data supporting both of our programs, we will also be reporting on our two clinical trials in progress.
  • We look forward to participating in this important event.”

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Retrieved on: 
Monday, March 25, 2024
Moyamoya disease, Cardiovascular disease, Congress, Risk, Patient, NAMS, American College, Ezetimibe, Clinical trial, FDC, ACC, ASCVD

ROSE2 evaluated obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; full results from the trial were previously presented at the National Lipid Association Scientific Sessions in June 2023.

Key Points: 
  • ROSE2 evaluated obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; full results from the trial were previously presented at the National Lipid Association Scientific Sessions in June 2023.
  • At ACC, NewAmsterdam will share new data demonstrating obicetrapib and ezetimibe’s impact on small dense LDL-C, a robust predictor of residual risk of future cardiovascular events.
  • NewAmsterdam recently initiated TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC (‘fixed-dose combination”) in adult patients with Heterozygous Familial Hypercholesterolemia (“HeFH”) and/or Atherosclerotic Cardiovascular Disease (“ASCVD”) or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.
  • Details of the presentation are as follows:
    Presentation at the 2024 American College of Cardiology (ACC) Congress:

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, March 25, 2024
Research, FASN, Fatty liver disease, Congress, Exercise, Progression-free survival, F2, Patient, SAN, Food and Drug Administration, F3, G&A, IPO, Obesity, IND, Acne, Bevacizumab, Glioblastoma, Fibrosis, Clinical trial, NASH, FDA, Drug development, Pharmaceutical industry

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today reported financial results for the full year ended December 31, 2023, and provided corporate updates.

Key Points: 
  • In January 2024, Sagimet sold 9,000,000 shares of its Series A common stock in an underwritten public offering and received $104.7 million in net proceeds.
  • In November 2023, Sagimet presented preclinical data evaluating denifanstat alone or in combination with semaglutide in mouse models of MASH at the 7th Obesity and NASH Drug Development Summit.
  • In October 2023, Sagimet’s license partner for China, Ascletis Bioscience Co. Ltd. (Ascletis), presented Phase 2 topline results at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.
  • In July 2023, Sagimet closed an upsized IPO of Series A common stock, at a public offering price of $16.00 per share.

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on: 
Saturday, March 23, 2024
Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points: 
  • WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
  • “We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
  • UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
  • The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

NCLA Asks en Banc Fifth Circuit to Vacate Legally Defective Nasdaq Board Diversity Rules

Retrieved on: 
Friday, March 22, 2024
Speech, Administration, Congress, Exchange, Public policy, Constitutional right, NCLA, Financial adviser

These Rules impose gender, race and sexual orientation quotas on corporate board membership for Nasdaq-listed companies.

Key Points: 
  • These Rules impose gender, race and sexual orientation quotas on corporate board membership for Nasdaq-listed companies.
  • A Fifth Circuit panel had upheld the Board Diversity Rules, but the en banc court granted NCLA’s request to rehear the case.
  • The Fifth Circuit panel in this case deferred to that flawed reasoning without addressing the statutory prohibitions that should invalidate the Rules.
  • NCLA looks forward to the en banc Fifth Circuit’s addressing each of these problems in turn.

VA STAND Act introduced in the United States Senate

Retrieved on: 
Friday, March 22, 2024
House, SCI/D, Disability, Congress, Face, House Committee, Health, Ranking, Robotics, DBA, ReWalk, Senate, Representative, Legislation, Rehabilitation

6373, the VA Spinal Trauma Access to New Devices (STAND) Act.

Key Points: 
  • 6373, the VA Spinal Trauma Access to New Devices (STAND) Act.
  • The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).
  • The bill also requires VA to report to Congress on their performance regarding the exams and device placements and holds local and regional VA medical centers accountable for performance against these same metrics.
  • The Senate bill comes on the same day that ReWalk device user and U.S. Marine Corps Veteran, Brittany Elliott, testified in a legislative hearing in front of the House Committee on Veterans' Affairs, Subcommittee on Health regarding the STAND Act.